This efficacy extends to first-line treatment in advanced NSCLC patients without driver mutations, patients with EGFR functional mutations who have failed prior EGFR-TKI therapy, and those who have failed previous systemic platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.